Is combined treatment with fenofibrate and ezetimibe safe and efficacious in patients with mixed hyperlipidemia?: Commentary

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 11, 2006, Pages 594-595

  Davidson, Michael H ^a,b,c  

^a Department Medicine ^*  (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c RADIANT RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; EZETIMIBE; FENOFIBRATE; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLECYSTECTOMY; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; LIVER TOXICITY; MIXED HYPERLIPIDEMIA; MONOTHERAPY; MYOPATHY; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME;

EID: 33750283203     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0689     Document Type: Short Survey

References (4)

1. Kosoglou T et al. (2005) Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44: 467-494
2. Merck/Schering-Plough Pharmaceuticals (2002) Zetia® (ezetimibe) package insert. MSP Marketing Services, West Point, PA
3. Farnier M et al. (2005) Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 26: 897-905
4. Davidson MH (2006) Statin/fibrate combination in patients with metabolic syndrome or diabetes: Evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 5: 145-156